Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”
We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc.
Posts Tagged ‘NASDAQ:ARWR’
Jim Cramer’s Thoughts on These 12 Stocks
On Tuesday’s episode of Mad Money, host Jim Cramer expressed concern over how President Donald Trump's actions have been impacting the stock market as he pointed out the confusion...
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript May 12, 2025Arrowhead Pharmaceuticals, Inc. beats earnings expectations.
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential
On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps.
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript February 10, 2025Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript November 26, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
Potomac Wealth Advisors president Mark Avallone joined CNBC's 'The Exchange' on November 16 to discuss where he sees investing opportunities following Trump's election.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript August 8, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.78.
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?
Baron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
12 High Growth Healthcare Stocks to Buy
The healthcare sector proved its mettle in 2022.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode.
Baron Funds Sold Arrowhead Pharmaceuticals (ARWR) to Reallocate to Higher Conviction Ideas
Baron Funds, an asset management company, released its “Baron Global Advantage Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
Baron Funds: “We Retain Conviction in Arrowhead (ARWR)”
Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Top 5 Stock Picks of Frank Fu’s CaaS Capital
In this article, we discuss the top 5 stock picks of Frank Fu's CaaS Capital.
Should I Avoid Arrowhead Pharmaceuticals Inc. (ARWR)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Is it a Good Thing to Keep Your Arrowhead Pharmaceuticals (ARWR) Shares?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be ...
Is Arrowhead Pharmaceuticals (ARWR) Still a Great Investment Pick?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.
Hedge Funds Are Piling Into Arrowhead Pharmaceuticals Inc. (ARWR)
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money ...
Is Arrowhead Pharmaceuticals (ARWR) A Good Stock To Buy Now?
Baron Opportunity Fund recently published its second-quarter commentary – a copy of which can be downloaded here.
Here is What Hedge Funds Think About Arrowhead Pharmaceuticals Inc. (ARWR)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2021 investor letter – a copy of which can be downloaded here.
Should You Retain Your Arrowhead Pharmaceuticals (ARWR) Position?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here.
Is ARWR Stock A Buy or Sell?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Is Arrowhead Pharmaceuticals (ARWR) Stock a Buy For 2021?
Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here.
Is ARWR A Good Stock To Buy Now According To Hedge Funds?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity...
Hedge Fund and Insider Trading News: Mike Novogratz, Crispin Odey, Steve Cohen, Fulcrum Asset Management, Elliott Management, Envestnet Inc (ENV), Arrowhead Pharmaceuticals Inc (ARWR), and More
Bitcoin is like "digital gold" and won't be used in the same way as traditional currency for at least the next five years, billionaire investor Mike Novogratz told Bloomberg on...
Hedge Fund and Insider Trading News: Ray Dalio, Balyasny Asset Management, Asia Research and Capital Management, Alcur Select, Lam Research Corporation (LRCX), Enghouse Systems Limited (EGHSF), and More
Bridgewater Associates founder Ray Dalio is giving $50 million to NewYork-Presbyterian to fight health inequality at a time when the coronavirus pandemic has laid bare the disproportionate...
Arrowhead Pharmaceuticals Inc. (ARWR) Fell Out Of Favor With Hedge Funds
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Did Hedge Funds Make The Right Call On Arrowhead Pharmaceuticals Inc. (ARWR) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Is Arrowhead Pharmaceuticals Inc. (ARWR) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR)
Coronavirus is probably the #1 concern in investors' minds right now. It should be.
Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money ...
Hedge Funds Have Never Been More Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR)
Is Arrowhead Pharmaceuticals, Inc.
Hedge Fund and Insider Trading News: Ken Griffin, Tom Steyer, Amber Capital, Acadia Pharmaceuticals Inc. (ACAD), and More
PARIS (Reuters) - Activist shareholder Amber Capital, which is being sued by Lagardere (LAGA.PA), said on Monday the lawsuit was baseless and it would continue to seek strategy...
Is Arrowhead Pharmaceuticals Inc (ARWR)’s Recently Published U.S. Patent Application A Blockbuster?
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) business model of going after extrahepatic targets and establishing first mover advantage has the potential to be amplified by gaining...
Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR)
A market surge in the first quarter, spurred by easing global macroeconomic concerns and Powell's pivot ended up having a positive impact on the markets and many hedge funds as...
Here’s What Hedge Funds Think About Arrowhead Pharmaceuticals, Inc. (ARWR)
Is Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR): Hedge Funds Are Snapping Up
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers...
Hedge Fund and Insider Trading News: Marc Lasry, Elliott Management, Third Point LLC, StealthGas Inc. (GASS), Pivotal Software Inc (PVTL), and More
Who knows what’s moving markets? Marc Lasry says he knows. It’s politics, and concern the Democrats will triumph in next week’s midterms.
